Gensight Biologics (XPAR:SIGHT) Buildings And Improvements : €4.92 Mil (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Gensight Biologics Buildings And Improvements?

Gensight Biologics's quarterly buildings and improvements declined from Dec. 2022 (€5.66 Mil) to Jun. 2023 (€5.39 Mil) and declined from Jun. 2023 (€5.39 Mil) to Dec. 2023 (€4.92 Mil).

Gensight Biologics's annual buildings and improvements increased from Dec. 2021 (€4.76 Mil) to Dec. 2022 (€5.66 Mil) but then declined from Dec. 2022 (€5.66 Mil) to Dec. 2023 (€4.92 Mil).

Gensight Biologics Buildings And Improvements Historical Data

The historical data trend for Gensight Biologics's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gensight Biologics Buildings And Improvements Chart

Gensight Biologics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Buildings And Improvements

Get a 7-Day Free Trial

4.68

4.46

4.76

5.66

4.92

Gensight Biologics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Buildings And Improvements	Get a 7-Day Free Trial															4.76	5.42	5.66	5.39	4.92

Gensight Biologics Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction. Broker and architect fees, permits, etc. can be covered within this category. Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized. Improvements are commonly recorded at acquisition cost. Building improvement examples include roofing, remodeling, replacements, etc.

Gensight Biologics (XPAR:SIGHT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gensight Biologics SA (XPAR:SIGHT) » Definitions » Buildings And Improvements

Comparable Companies

Traded in Other Exchanges

GSGTF:USA G49N:Germany

Address

74,rue du Faubourg Saint-Antoine, Paris, FRA, 75012

Website

https://www.gensight-biologics.com

Gensight Biologics SA is a clinical-stage biotechnology group discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence, and Optogenetics, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. The group focus is on ophthalmology where it develops product candidates to restore eyesight to patients suffering from retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.

Gensight Biologics (XPAR:SIGHT) Headlines

No Headlines